Abstract
Oral mucositis (OM) is a significant problem in patients with head and neck cancer undergoing chemoradiation treatments. Severe OM develops in more than 90% of patients undergoing combined chemotherapy and radiation. OM is not only painful but also limits adequate nutritional intake and decreases the patient’s willingness to continue treatment. When severe, it is responsible for acute and chronic complications such as aspiration, prolonged dysphagia, scarring and fibrosis. In spite of all the advances made in understanding the pathobiology of OM, there is currently no prophylactic therapy with proven efficacy. Strategies to limit the extent of OM and to manage its symptoms include basic oral care, supportive medications, nutritional support and limiting the use of aggressive treatments to high-risk patients. This review focuses on OM recognition, preventive measurements, symptom-management strategies, and identifies current research studies addressing OM prevention.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
